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Introduction {#sec005}
============

Colon cancer is one of the most aggressive digestive system cancers worldwide; and its incidence rate in China has been increasing dramatically over the years \[[@pone.0218839.ref001], [@pone.0218839.ref002]\]. Due to its distant metastasis and high recurrence rate, colon cancer patients often have a poor prognosis. Although a large number of genes associated with the metastasis and recurrence of colon cancer have been identified, the molecular pathogenesis of this disease is still far from being fully elucidated. Therefore, identification of new genes associated with colon cancer progression is of great importance for the prevention, early and accurate diagnosis, and treatment of the disease.

PRR14 (Proline Rich Protein 14) is a member of the proline-rich protein family. It contains one proline-rich region flanked by N- and C-terminal nuclear localization signals \[[@pone.0218839.ref003]\]. The proline rich domain participates in multiple protein interactions by binding to various domains \[[@pone.0218839.ref004], [@pone.0218839.ref005]\]. During cell cycle progression, PRR14 presents a dynamic distribution with a periodic disintegration and reconstruction of the nuclear lamina, and its function is to target the HP1-labeled heterochromatin to locate in the nuclear lamina during mitotic exit \[[@pone.0218839.ref003], [@pone.0218839.ref006]\]. In skeletal muscles, PRR14 promotes myogenesis via the maintenance of the nuclear lamina structure and the stimulation of the activity of MyoD \[[@pone.0218839.ref007]\].

Interestingly, PRR14 has been implicated in the development of tumors and cancers. PRR14 is amplified and aberrantly overexpressed in lung cancer, and promotes lung cancer cells proliferation through the activation of the PI3K/AKT/mTOR signaling pathway. Its proline-rich peptide alone can activate the PI3K pathway to promote the proliferation of lung cancer cells *in vitro* and tumorigenesis *in vivo* \[[@pone.0218839.ref008]\]. The expression of PRR14 in a variety of tumors in the TCGA database has also been analyzed, and it has been found that PRR14 is commonly elevated in a variety of tumors, including colon cancer \[[@pone.0218839.ref009]\]. Besides, it has been reported that PRR14 can be used as an independent prognostic marker and may be a potential therapeutic target in the treatment of non-small cell lung cancer (NSCLC) \[[@pone.0218839.ref010]\]. PRR14 promotes the growth of breast cancer cells by regulating the Ras pathway \[[@pone.0218839.ref011]\]. To date, the role of PRR14 in colon cancer has not been reported.

In this study, we have investigated the possible role of PRR14 in colon cancer, by which we explored PRR14 expression in colon cancer, and studied the effects of its knockdown on the proliferation, migration and invasion of colon cancer cells, as well the formation of pseudopodia.

Materials and methods {#sec006}
=====================

Cell line and cell culture {#sec007}
--------------------------

Human colon cancer cell lines, HCT116 and RKO, were purchased from ATCC. The cell lines were maintained in DMEM high glucose medium with 10% FBS (Invitrogen,USA) and penicillin (100 IU/ml) /streptomycin (100 mg/ml). Cells were incubated at 37 ^**o**^C in a humidified atmosphere of 5% CO~**2**~.

Tissue array and immunohistochemistry {#sec008}
-------------------------------------

PRR14 protein expression was detected on a colon cancer tissue array slide from Shanghai Outdo Biotech CO. (HColA160CS01, Shanghai, China). The tissue array contained human colon cancer tissues and their corresponding adjacent normal tissues (80 cases). The primary antibody used was rabbit anti-PRR14 antibody(1:2000, HPA060265, Sigma, USA). IHC experiments were carried out routinely. IHC staining scores were as follows: The scoring standards of the staining intensity were: 0 (no staining), 1 (light yellow staining), 2 (brown and yellow staining) and 3 (brown staining). The scoring standards for the percentage of positive cells under the microscope were: 0 (\<5%), 1 (5--25%), 2 (25--50%), 3 (51--80%), and 4 (\>80%). The final score was obtained by multiplying the stain intensity score by the positive cell percentage score, where \<7 was low and ≥ 7 was high.

Bioinformatics analysis {#sec009}
-----------------------

The comparison of PRR14 expression level in colon cancer tissues and normal tissues was performed using the GEPIA database ([http://gepia.cancer-pku.cn](http://gepia.cancer-pku.cn/)) \[[@pone.0218839.ref012]\] and the Oncomine database ([https://www.oncomine.org](https://www.oncomine.org/)) \[[@pone.0218839.ref013]\]. The Hong Y Dataset (GSE9348) of Oncomine was used \[[@pone.0218839.ref014]\]. The patient survival data of TCGA was obtained from the Human Protein Atlas database ([https://www.proteinatlas.org](https://www.proteinatlas.org/)). The optimal cut-off value for PRR14 expression level was determined using SPSS ROC curve analysis. The survival curve was estimated using Kaplan-Meier analysis, and the *P*-values were calculated with the log-rank (Mantel-Cox) test.

siRNA synthesis and transfection {#sec010}
--------------------------------

The siRNA against PRR14 and negative control (NC) siRNA were synthesized by Shanghai GenePharma Co. (Shanghai, China). The SiRNA sequences were referred to a previous study \[[@pone.0218839.ref003]\]. The sense sequence of the siRNA for PRR14-1 was: `5'-GCU AGA AGA UGU CAU GGC UTT-3'`, and the antisense sequence for PRR14-1 was: `5'-AGC CAU GAC AUC UUC UAG CTT-3'`. The sense sequence for PRR14-2 was: `5'-GGA CUG CCU CGA CCA AUC ATT-3'`, and the antisense sequence for PRR14-2 was: `5'- UGA UUG GUC GAG GCA GUC CTT-3'`. The sense sequence for the negative control was: `5'-UUC UCC GAA CGU GUC ACG UTT-3'`, and the antisense sequence for the negative control was: `5'- ACG UGA CAC GUU CGG AGA ATT-3'`. The siRNA was transfected into the cells at 30nM concentration using Lipofectamine RNAiMAX reagent (13778--150, invitrogen) according to the manufacturer's instructions. Cells were collected and analyzed 48h after transfection.

RNA isolation and RT-PCR {#sec011}
------------------------

Total RNA was isolated using RNA-simple Total RNA kit (DP419, Tiangen Biotech Co., Beijing, China) according to the manufacturer\'s instructions. Reverse transcription was done using ReverTra Ace qPCR RT kit (FSQ-101, Toyobo Co., Osaka, Japan). The RT-PCR assay was performed using SYBR Green PCR Master Mix (QPK-212, Toyobo Co.) on the CFX96 real-time PCR detection system (Bio-Rad, USA). The gene-specific primer sequences are listed in [S1 Table](#pone.0218839.s002){ref-type="supplementary-material"}. GAPDH was used for quantitative internal referencing. The 2^--ΔΔCt^ method was used to analyze the results.

Western blot {#sec012}
------------

After 48h of siRNA transfection, the cells were collected and lysed with T-PER^TM^ Tissue Protein Extraction Reagent (Thermo Scientific, USA) containing protease inhibitor and phosphatase inhibitor (Roche, Mannheim, Germany). The protein concentration was determined with the BCA kit (Thermo Scientific). The western blot experiment was carried out in accordance with the routine experimental steps. The following primary antibodies were used: the rabbit anti-PRR14 antibody (1:500, HPA060265, Sigma, USA), rabbit anti-CDK2 antibody (1:1000, SAB4300388, Sigma), rabbit anti-P21 antibody and P27 antibody (1:1000, 9932T, Cell Signaling technology, USA), rabbit anti-E cadherin antibody (1:200, BM3903, Boster, China), rabbit anti-N cadherin antibody (1:500, RLT2988, Ruiying Biological, China), mouse anti-Vimentin antibody(1:500, 60330-1-IG, Proteintech, China), rabbit anti-twist1 antibody (1:1000, SAB2108515, Sigma), rabbit anti-AKT antibody (1:1000, 4691T, Cell Signaling technology), rabbit anti-phospho-AKT^(Thr308)^ antibody (1:1000, 13038T, Cell Signaling technology), rabbit anti-phospho-AKT^(Ser473)^ antibody (1:1000, 4060T, Cell Signaling technology), mouse anti-GAPDH antibody (1:1000, AF0006, Beyotime, China). The secondary antibody used (goat anti-rabbit or goat anti-mouse secondary antibody) was conjugated to horseradish peroxidase (1:2000; Beyotime). Chemiluminescence pictures were taken using the Super Signal Sensitivity Substrate Kit (Pierce, Thermo Scientific) with the Chemi Doc XRS imaging system (Bio-Rad, USA).

Cell proliferation assay {#sec013}
------------------------

Cell proliferation was measured using the CCK8 reagent (HY-k0301, MedChemExpress, USA). Briefly, cells transfected with siRNA for 24 hours were counted and placed into 96-well plates with 1500 cells per well. 100μl DMEM containing 10% CCK8 reagent was added into the cells per well at 0h, 24h, 48h, and 72h, respectively. The cells were incubated at 37 ^o^C for 1h in a humidified atmosphere of 5% CO~2~. Absorbance was measured at a wavelength of 450nm by using the Varioskan Flash microplate reader (Thermo Scientific, USA).

Cell cycle and apoptosis analysis {#sec014}
---------------------------------

For cell cycle analysis, cells were centrifuged and collected 48h after transfection, washed once with cold PBS, then fixed with 70% ethanol at 4 ^o^C refrigerator overnight. The fixed cells were centrifuged and collected the next day, washed twice with cold PBS, stained with PI containing RNase (c1052,Beyotime Biotechnology, China), and incubate at 37 ^o^C in the dark for half an hour. Apoptosis detection was carried out using the FITC Annexin V Apoptosis Detection Kit with PI (640914, Biolegend, USA). Cells were washed twice with cold BioLegend\'s Cell Staining Buffer (Biolegend), and then resuspended in Annexin V Binding Buffer at a concentration of 1.0 x10^6^ cells/ml. 100μl of the cell suspension was transferred into a 1.5ml test tube. 5μl of FITC Annexin V, followed by 10μl of Propidium Iodide Solution, was added to the cell suspension. The cells were gently vortexed and incubated in the dark for 15min at room temperature. 400μl of Annexin V Binding Buffer was added to each tube. The apoptotic samples were detected with flow cytometry (BD Biosciences, USA).

Tumor xenografts {#sec015}
----------------

Female nude mice were maintained in pathogen free conditions and used at 5--6 weeks of age. Animal ethics was approved by the Laboratory Animal Center of Chongqing Medical University. The mice were anesthetized with isoflurane controlled by small animal anesthesia machine. The siNC and siPRR14 HCT116 cells suspension (5 x 10^5^ cells in 100ul PBS per point) were injected with insulin syringe into the left and right dorsal flank of the mice, respectively. About 30 days after injection, the mice were sacrificed by tearing the cervical vertebra and dissected, tumor samples were taken, and the length, width and weight of the tumor were measured. The volume was calculated by using the modified ellipsoid formula: volume = 1/2 (length x width^2^).

Wound healing, migration and invasion assays {#sec016}
--------------------------------------------

For wound healing assay, the cells were digested and counted. 1 x 10^6^ cells were seeded into each well of a 24-well plate, and incubated overnight. The cells were scratched in the middle of the plate with white pipette tips, washed with PBS for 3 times to remove the floating cells, and then photographed at 0h, 24h and 48h respectively. Transwell Chambers with multiporous 8μm pore size PET membranes (MCEP24H48, Millipore, Germany) were used for the migration and invasion assays. 2 x 10^5^ cells were resuspended in 200μl serum-free medium and inoculated into the upper chamber. 500ml medium containing 10% FBS was added into the lower chamber. The cells were incubated at 37°C in a humidified atmosphere of 5% CO~2~ for 24h, and then fixed with polyformaldehyde for 20min. Thereafter, they were washed 3 times with PBS, stained with crystal violet for 10min, and washed 3 times with PBS. The cells in the upper chamber were then gently wiped off with cotton swab, and the cells in the lower chamber were photographed.

Immunofluorescent assay {#sec017}
-----------------------

For Brdu assay, 48h after siRNA transfection, cells were incubated with Brdu (ab142567, abcam, USA) for 1h, fixed with 4% paraformaldehyde for 20min, permeabilized with 0.3% triton for 15min, treated with 2M HCl for 20min, balanced with sodium tetraborate for 5min, and then blocked with 5% BSA for 1h. After fixation, cells were incubated with rabbit anti-PRR14 antibody (1:200,HPA060265,Sigma) or rat anti-Brdu antibody (1:300,ab6326,abcam,USA) at 4 ^o^C overnight, followed by incubation with the secondary antibody at room temperature for 1 hour. For phalloidin staining, cells were fixed and permeabilized, then stained with TRITC-Phalloidin (40734ES75, Yeasen, China) for 1h at room temperature. The nuclei were stained with DAPI for 10min, and the Zeiss LSM 780 laser confocal microscope was used for photography.

Statistical analysis {#sec018}
--------------------

Results are shown as mean ± SD. Statistical evaluation was performed with SPSS. The student *t* test was used to determine differences between groups. The χ^2^ test was used to examine the relationship between the protein expression of PRR14 and the clinicopathological factors. Statistical significance was set at \*\**P*\<0.01 and \**P*\<0.05. Graphs were prepared using Graphpad Prism 6.0.

Results {#sec019}
=======

PRR14 is highly expressed in colon cancer, and this correlates with poor prognosis of the disease {#sec020}
-------------------------------------------------------------------------------------------------

Firstly, we used the GEPIA database to investigate the expression pattern of PRR14 in colon cancer. The data showed that the mRNA expression of PRR14 was higher in the cancer tissues than in the normal tissues. PRR14 expression was significantly correlated with tumor grade ([Fig 1A and 1B](#pone.0218839.g001){ref-type="fig"}). The data from oncomine database also demonstrated a higher expression of PRR14 in tumor tissues ([Fig 1C](#pone.0218839.g001){ref-type="fig"}). The TCGA survival data from the human Protein Atlas database showed that higher PRR14 expression was associated with worse patient outcomes ([Fig 1D](#pone.0218839.g001){ref-type="fig"}). We also evaluated PRR14 expression by using tissue microarray from clinical patients. PRR14 positive signal was mainly detected in the nucleus of non-neoplastic epithelium cells and tumor cells, and PRR14 staining was obviously stronger in the cancer tissues than in the adjacent normal tissues ([Fig 1E and 1F](#pone.0218839.g001){ref-type="fig"}). The results of the comparison of the expression of PRR14 among the clinicopathological features of colon cancer is displayed in [Table 1](#pone.0218839.t001){ref-type="table"}. The table shows that PRR14 expression in colon cancer was strongly associated with tumor size (*P* = 0.012), distant metastasis (*P* = 0.045) and TNM stage (Tumor Node Metastasis stage) (*P* = 0.029), but not with the gender and age of the patients.

![PRR14 expression in colon cancer.\
(A) Expression of PRR14 in cancer tissues and their corresponding adjacent normal tissues was analyzed from the online GEPIA database. (B) PRR14 expression in different grades of colon cancer samples was analyzed from the GEPIA database. (C) Expression of PRR14 in cancer tissues and adjacent normal tissues was analyzed from the online oncomine database. (D) Survival curve of the overall survival rate with High PRR14 and Low PRR14 expression was analyzed from the TCGA data of the Human Protein Atlas database. (E) Representative immunohistochemistry images of PRR14 expression in colon cancer tissues and their corresponding adjacent normal tissues. (F) Immunohistochemistry scores of PRR14 expression in the colon cancer tissues were significantly higher compared to the corresponding adjacent normal tissues. Scale bar, 100μm.](pone.0218839.g001){#pone.0218839.g001}

10.1371/journal.pone.0218839.t001

###### The relationship between PRR14 expression levels and clinicopathological characteristics of colon cancer patients.

![](pone.0218839.t001){#pone.0218839.t001g}

  -----------------------------------------------------------------------------------------------------------------
  Clinicopathological features   Number of patients   PRR14 expression status   *P*                         
  ------------------------------ -------------------- ------------------------- ------------- ------------- -------
  Gender                         Male\                43\                       20 (46.5%)\   23 (53.5%)\   0.617
                                 Female               37                        19 (51.4%)    18 (48.6%)    

  Age                            ≥60\                 55\                       27 (49.1%)\   28 (50.9%)\   0.928
                                 \<60                 25                        12 (48%)      13 (52%)      

  Tumour size                    ≥6cm\                34\                       11 (32.4%)\   23 (67.6%)\   0.012
                                 \<6cm                46                        28 (60.9%)    18 (39.1%)    

  Lymph node metastasis          negative\            54\                       30 (55.6%)\   24 (44.4%)\   0.079
                                 positive             26                        9 (34.6%)     17 (65.4%)    

  Distant metastasis             negative\            76\                       39 (51.3%)\   37 (48.7%)\   0.045
                                 positive             4                         0 (0%)        4 (100%)      

  TNM stage                      Ⅰ、Ⅱ\                52\                       30 (57.7%)\   22 (42.3%)\   0.029
                                 Ⅲ、Ⅳ                 28                        9 (32.1%)     19 (67.9%)    
  -----------------------------------------------------------------------------------------------------------------

χ^2^ test was used for comparison between PRR14^low^ and PRR14^high^ tissues.

Knockdown of PRR14 inhibited cell growth *in vitro* and *in vivo* {#sec021}
-----------------------------------------------------------------

To investigate the biological function of PRR14 *in vitro*, we knocked down PRR14 in two colon cancer cell lines--HCT116 and RKO--via siRNA-mediated gene silencing. The knockdown efficiency was determined by RT-PCR and western blot. The PCR results showed that the two siRNAs had a knockdown effect on the mRNA levels ([Fig 2A](#pone.0218839.g002){ref-type="fig"}), while the western blot results showed that siRNA-2 had a better knockdown effect at the protein level ([Fig 2B](#pone.0218839.g002){ref-type="fig"}). Therefore, siRNA-2 was selected for the following cell experiments. Immunofluorescence results also showed that the knockdown effect of siRNA-2 was obvious, and the enlarged figure showed that PRR14 expression was mainly located in the nuclear membrane and nucleus of cells, with a small amount of staining in the cytoplasm ([Fig 2C](#pone.0218839.g002){ref-type="fig"}).

![Colon cancer cells proliferation following PRR14 depletion.\
(A&B) The efficiency of siRNA interference was analyzed by (A) qRT-PCR and (B) Western blot assays. (C) Immunofluorescence assay of PRR14 expression in HCT116 cells. (D&E) The proliferation of HCT116 and RKO cells following PRR14 depletion. (F) PRR14 depletion inhibited colony formation of HCT116 and RKO cells. (G) Representative images of nude mouse subcutaneous tumors from HCT116 cells transfected with siNC and siPRR14. (H) The volume and the weight of the tumors were measured (\*: *P* \< 0.05; \*\*: *P* \< 0.01).](pone.0218839.g002){#pone.0218839.g002}

We analyzed the effect of PRR14 on colon cancer cell growth using the CCK8 assay. The results showed that the cell proliferation rate was decreased in both HCT116 and RKO cells after transfection with the PRR14 siRNA ([Fig 2D and 2E](#pone.0218839.g002){ref-type="fig"}). Meanwhile, PRR14 did not affect the rate of apoptosis in both cell lines ([S1 Fig](#pone.0218839.s001){ref-type="supplementary-material"}). Furthermore, colony formation assay showed that PRR14 knockdown significantly reduced the clonogenic ability of the cells ([Fig 2F](#pone.0218839.g002){ref-type="fig"}). Subcutaneous tumorigenesis experiment showed that the tumor volume and weight were significantly lower in the knockdown group than in the control group ([Fig 2G and 2H](#pone.0218839.g002){ref-type="fig"}). These results show that PRR14 plays a role in the growth of colon cancer cells.

Knockdown of PRR14 resulted in cell cycle arrest at G1 phase {#sec022}
------------------------------------------------------------

To test the mechanism by which PRR14 affects proliferation, we examined the cell cycle of cells after RNA interference. Results showed that knockdown PRR14 resulted in cell arrest at G1 phase and a significantly lower proportion of cells at S phase ([Fig 3A](#pone.0218839.g003){ref-type="fig"}). Brdu labeling assay also indicated that the proportion of S-phase cells decreased ([Fig 3B](#pone.0218839.g003){ref-type="fig"}).

![The impact on cell cycle progression of colon cancer cells following PRR14 depletion.\
(A) Cell cycle analysis in HCT116 and RKO cells transfected with siNC and siPRR14 siRNA by flow cytometry,and the average percentage of G0/G1,S,G2/M phases was calculated. (B) Representative immunofluorescence images of Brdu staining of HCT116 and RKO cells transfected with siNC and siPRR14 siRNA. The number of Brdu labeled positive cells was calculated to reflect the proportion of S-phase cells (\*:*P* \< 0.05;\*\*: *P*\< 0.01). scale bar,50um.](pone.0218839.g003){#pone.0218839.g003}

Knockdown of PRR14 inhibited cell migration and invasion {#sec023}
--------------------------------------------------------

The scratch-wound assay and transwell assay were performed to assess the effects of PRR14 on migration and invasion of HCT116 and RKO cells. The scratch assay showed that the wound healing time in the PRR14 siRNA group was significantly slower than in the control siRNA group ([Fig 4A](#pone.0218839.g004){ref-type="fig"}). The transwell experiment and matrigel coated transwell experiment showed that the migration and invasion ability of the siRRR14-treated cells were decreased ([Fig 4B](#pone.0218839.g004){ref-type="fig"}). This suggest a role of PRR14 in the migration and invasion of colon cancer.

![The impact on migration and invasion of colon cancer cells following PRR14 depletion.\
Cell migration or invasion was evaluated by using (A) would healing assay (B) transwell migration and invasion assay in HCT116 and RKO cells, respectively. (\*\*: *P* \< 0.01).](pone.0218839.g004){#pone.0218839.g004}

Knockdown of PRR14 affected the expression of EMT-related genes and the formation of pseudopodia {#sec024}
------------------------------------------------------------------------------------------------

Interference with PRR14 in mesenchymal-like HCT116 and RKO cells resulted in an obvious shift from scattered spindle-shaped cells to clustered round-shaped cells ([Fig 5A](#pone.0218839.g005){ref-type="fig"}). We found that knockdown of PRR14 inhibited EMT, as evidenced by the up-regulation of E-cadherin expression and the down-regulation of N-cadherin, Vimentin, and Twist1 expressions ([Fig 5B](#pone.0218839.g005){ref-type="fig"}). Further, we examined the protein expression of PRR14 and EMT makers in the different xenografts. We pooled tumors of two groups (No.9 and 10) since their small size. Western blot results and statistics analysis showed that the mesenchymal indicator Twist1 and Vimentin were highly expressed in xenografts with control cells, and the epithelial indicator E-cadherin was generally highly expressed in xenografts with PRR14 knockdown cells ([Fig 5C and 5D](#pone.0218839.g005){ref-type="fig"}). By immunofluorescent labeling of actin filaments, we found that the number of pseudopodia in the cells was significantly reduced ([Fig 5E](#pone.0218839.g005){ref-type="fig"}). These results demonstrate that PRR14 may affect colon cancer metastasis by regulating EMT and cytoskeletal remodeling.

![Modulation of EMT and the formation of pseudopodia in the colon cancer cells following PRR14 depletion.\
(A) Morphologic changes in mesenchymal HCT116 and RKO cells after transfection with siNC and siPRR14. Scale bar, 50 μm. (B) Western blot was used to detect the expression of genes controlling EMT in HCT116 and RKO cells transfected with siNC and siPRR14. (C) Western blot detection of the PRR14 and EMT indicators expression in xenograft tumor cells. (D) Statistics comparison of PRR14 and EMT indicators protein level in the xenografts. (E) Representative immunofluorescence images of phalloidin staining of HCT116 and RKO cells transfected with siNC and siPRR14, and the calculated proportion of pseudopod-positive cells. scale bar, 50 μm. (\*\*: *P* \< 0.01).](pone.0218839.g005){#pone.0218839.g005}

Knockdown of PRR14 affected the expression of cell cycle-related genes and AKT pathway genes {#sec025}
--------------------------------------------------------------------------------------------

To clarify the mechanism by which PRR14 regulates the cell cycle, we knocked down PRR14 and examined its effects on the expression of cell cycle regulatory genes. Knockdown of PRR14 in HCT116 and RKO cells significantly inhibited CDK2 mRNA expression and protein expression ([Fig 6A, 6B and 6C](#pone.0218839.g006){ref-type="fig"}). In HCT116 cells, the mRNA level of CDK1, CCNA, CCNB, CCND1 and CDK kinase inhibitors--P21 and P27 were found to be elevated, while no significant change in RKO cells ([Fig 6A and 6B](#pone.0218839.g006){ref-type="fig"}). We also found that P21 and P27 protein level was elevated both in HCT116 and RKO cells ([Fig 6C](#pone.0218839.g006){ref-type="fig"}). Moreover, knockdown of PRR14 inhibited the phosphorylation of AKT and its downstream gene, mTOR ([Fig 6D](#pone.0218839.g006){ref-type="fig"}). These results suggest that PRR14 modulates the cell cycle gene expression and acts on the AKT pathway during colon cancer progression.

![Effects of PRR14 depletion on the expression of genes regulating the cell cycle and the related pathway.\
(A&B) qRT-PCR was used to detect the cell cycle genes expression in HCT116 (A) and RKO cells (B) transfected with siNC and siPRR14. (C) Western blot was used to detect the cell cycle genes expression in HCT116 and RKO cells transfected with siNC and siPRR14. (D) Western blot was used to detect the AKT pathway gene expression in HCT116 and RKO cells transfected with siNC and siPRR14 siRNA. (\*: *P* \< 0.05; \*\*: *P* \< 0.01).](pone.0218839.g006){#pone.0218839.g006}

Discussion {#sec026}
==========

In this study, we found that PRR14 was significantly upregulated in colon cancer, and this is consistent with the results of previous analysis of the TCGA database \[[@pone.0218839.ref009]\]. PRR14 expression was associated with the malignant clinicopathological characteristics, including tumor size, distant metastasis and TNM stage of colon cancer. SiRNA-mediated gene silencing of PRR14 inhibited colon cancer cell proliferation, cell cycle progression, migration and invasion. This is in line with similar reports made about this gene in lung cancer cells and breast cancer cells \[[@pone.0218839.ref008]\]. Thus, these findings indicate a role of PRR14 in promoting tumor or cancer progression.

Malignant proliferation of tumor cells is associated with dysregulation of their cell cycle progression \[[@pone.0218839.ref015]\]. Cell cycle progression is precisely regulated by a series of periodic factors \[[@pone.0218839.ref016], [@pone.0218839.ref017]\]. We found that knockdown of PRR14 inhibited the expression of CDK2, a G1/S transition promoting gene, in both cell lines. Moreover, in HCT116 cells, the expressions of CDK1, CCNA, CCNB and CCND1 were also down-regulated and the expressions of CDK2 inhibitors--P21 and P27 were up-regulated, while in RKO cells, the expression of P21 and P27 protein levels were up regulated. These results suggest that PRR14 may promote malignant proliferation of colon cancer cells by disrupting cell cycle progression. Besides, the inconsistent mRNA levels of cell cycle genes in two cell lines indicating that the mechanism of PRR14 action may be inconsistent between the two cells in mRNA level. As the mRNA and protein of P21 and P27 are not consistent in RKO cells, we speculate that PRR14 may play a more important role in the post-translation level.

Numerous evidences show that cell phenotype and movement are related to EMT. EMT is considered to be a critical step in the process of metastasis in a variety of tumors \[[@pone.0218839.ref018], [@pone.0218839.ref019]\], including colon cancer \[[@pone.0218839.ref020]\]. It is a complicated process in which cells are transformed from epithelial phenotype to mesenchymal phenotype, thus gaining migration ability. In this study, silencing of PRR14 changed the cells' morphology, and decreased the expression of Twist1, an important transcription factor in the EMT process, which mediates the inhibition of E cadherin expression and the up-regulation of N cadherin expression. This indicates that PRR14 is involved in the EMT process. Since the cytoskeleton enhances pseudopodia formation during the motility of cancer cells \[[@pone.0218839.ref021]--[@pone.0218839.ref024]\], and PRR14 was found to regulate cytoskeletal remodeling, it could be stated that PRR14 promotes the metastasis of colon cancer cells by modulating the structure of the cytoskeleton.

The PI3K/AKT pathway is involved in the regulation of proliferation, apoptosis and migration in many tumors, including colon cancer. We have shown that silencing PRR14 induced changes in p-AKT and p-mTOR levels, indicating that PRR14 acts on PI3K/AKT pathway. This is consistent with observations made about lung cancer cells. It has been reported that PRR14 activates the PI3K/AKT pathway by binding with the SH3 domain of GRB2 \[[@pone.0218839.ref008]\]. GRB2 is widely expressed in a variety of cells and participates in many cellular functions by transducing the receptor tyrosine kinase (RTK) signaling pathway. The SH2 domain of GRB2 receives RTK signals on the cell membrane and mediates the signals to be transmitted to the downstream RAS/MAPK and PI3K/AKT pathways\[[@pone.0218839.ref025]--[@pone.0218839.ref027]\]. A previous study has shown that PRR14 functions in the nucleus to regulate the localization of heterochromatin \[[@pone.0218839.ref003]\]. How it binds to GRB2 in the cytoplasm, or whether it has other variants involved in GRB2 binding in the cytoplasm, is worth studying. Apart from acting on the PI3K pathway through GRB2, whether PRR14 has another mechanism through which it regulates the development and progression of colon cancer, remains to be determined. It has been reported that PRR14\'s proline-rich domain is involved in protein-protein interaction by binding to multiple domains \[[@pone.0218839.ref004], [@pone.0218839.ref005]\]. This suggests that PRR14 may interact with other unknown molecules in regulating colon cancer development and progression, and the identification of these molecules is our next research direction.

Conclusion {#sec027}
==========

PRR14 plays an important role in the development and progression of colon cancer, and is a possible prognostic marker and therapeutic target for the disease. Further exploration to elucidate its specific molecular mechanism is of great significance.

Supporting information {#sec028}
======================

###### Effect of PRR14 depletion on the apoptosis of HCT116 and RKO cells.

Representative images of apoptosis detection, and the proportion of the sum of early apoptosis and late apoptosis.

(TIF)

###### 

Click here for additional data file.

###### Genes-specific PCR primers.

(DOC)

###### 

Click here for additional data file.
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A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Jung Weon Lee, Ph.D.

Academic Editor

PLOS ONE

**Journal Requirements:**

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information on the animal research and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors investigated PRR14 (proline-rich protein 14) in colon cancer cells. Using multiple databases and a colon cancer tissue microarray, Fig. 1 shows that PRR14 is more highly expressed in colon cancer compared to non-cancer colon tissue. Higher PRR14 is correlated with lower survival. Using HCT116 and RKO colon cancer cell lines, Fig. 2 shows that siRNA knockdown of PRR14 slows proliferation and reduces tumor growth in xenografted mice. Fig. 3 shows PRR14 knockdown reduces invasion. Fig. 4 shows that reduction of PRR14 increases E-cadherin and reduces mesenchymal markers twist, vimentin, and N-cadherin and pseudopodia formation. In Fig. 5, PRR14 knockdown lowers some cell cycle markers and phosphor-AKT/mTOR. The authors conclude that PRR14 plays an important role in colon cancer and may possibly be used as a biomarker.

The literature on PRR14 is very little so not much is known on its function. Its potential role in colon cancer is suggested but the authors should be less emphatic that it has an important role. Some suggestions to help improve the quality of the paper is as follows:

1\. What is cellular localization of PRR14 in HCT/RKO cells? If predominantly nuclear, difficult to explain results. IHC in Fig. 1E is difficult to determine localization (higher mag as insert would help).

2\. What is effect of PRR14 knockdown on other signaling pathways such as ERK or JNK. Does PRR14 have a global role in intracellular signaling?

3\. What is the cell cycle profile with PRR14 (G1/S block?).

4\. Further comment on differences in PRR14 kd in 2 cell lines. E.g., p21/p27 mRNA; despite no change p27 mRNA, protein increased in RKO.

5\. Table 2 distant mets n=4 all with high PRR14 (100%), whereas low n=0 yet number in parenthesis is 48.8%; should be 0. How explain P=0.029 for TNM but 0.079 ln mets?

6\. Tumor xenografts\-\--presumably kd is transient if using siRNA. Level of PRR14 in tumors? How long after siRNA transfection does PRR14 kd last in vitro?

Reviewer \#2: The manuscript "PRR14 Overexpression Promotes Cell Growth, Epithelial to Mesenchymal Transition

and Metastasis of Colon Cancer via the AKT Pathway" by Fangfang Li

et al., investigates the molecular mechanism through wich PRR14, a member of the proline-rich protein family

partecipates to tumor progression. The experiments are well conceived, the manuscript is well written and I have only few comments on it.

Major comments

HCT116 and RKO

mesenchimal one. What happened if PRR14 is overexpressed (or silenced) in epithelial colon cancer cells? Some keys experiments should be presented in epithelial colon cancer cells.

On the same way it would be interest to see the effect of PRR14 overexpression in HCT116 and RKO cells. Also if the results are negative they should be presented.

Minor comments

The sentence "To clarify the mechanism by which PRR14 regulates the cell cycle

" at the beginning of the result section "Knockdown of PRR14 affected the expression of cell cycle-related genes and AKT

pathway genes" is not correct. Indeed the authors did not investigate at all the ability of PRR14 to regulate cell cycle but they address the point of its role in proliferation

(not in specific cell cycle phases).

Figure 5C is not mentioned in the text

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Carlos Perez-Stable

Reviewer \#2: Yes: Giulia Piaggio

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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PONE-D-19-15816R1

Dear Dr. Fu,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Jung Weon Lee, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: All my comments have been addressed. The manuscript is now acceptable for publication on PLOSONE journal.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Carlos Perez-Stable

Reviewer \#2: Yes: Giulia Piaggio
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Dear Dr. Fu:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jung Weon Lee

Academic Editor

PLOS ONE
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